QIAGEN’s GeneReader NGS System streamlines data management for labs
New middleware co-developed with Genohm ensures full chain of custody from Sample to Insight and integrates with most LIMS systems
Hilden, Germany, and Charlotte, NC, USA, November 09, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with lab informatics company Genohm to empower GeneReader NGS System users with seamless data management by integrating the NGS workflow with their laboratory information management systems (LIMS). QIAGEN’s Sample to Insight next-generation sequencing (NGS) solution is supported by GeneRead Link, a middleware co-developed by the two companies to ensure complete chain of custody from sample processing to final reports – with full connectivity into the leading LIMS systems. In addition, GeneReader NGS System customers who do not already have a LIMS solution can benefit from easy connectivity into Genohm’s proprietary SLims solution to help manage all data across the laboratory. Both companies will continue to enhance GeneRead Link and adapt the middleware solution as required to support future GeneReader workflows.
“The value of next-generation sequencing comes from the insights a lab generates, and our GeneReader NGS System is uniquely designed to enable any laboratory to deliver actionable results from NGS. We are pleased to partner with Genohm to deliver GeneRead Link, greatly simplifying management of the sequencing information and providing connectivity with most LIMS platforms,” said Jonathan Arnold, Senior Director of Marketing, Next Generation Sequencing, for QIAGEN. “Offering GeneReader NGS customers access to Genohm’s proprietary SLims solution, an easy-to-use LIMS and electronic laboratory notebook system, broadens the solution to manage the whole laboratory’s data.”
“Our focus is on making life in the lab easier”, said Frederik Decouttere, Genohm’s Chief Executive Officer of Genohm, “and working with QIAGEN enables us to offer Genohm’s user-friendly solutions to more customers around the globe, particularly clinical research and diagnostic labs deploying NGS. “SLims is a flexible, feature complete, compliant and easy-to-use solution consisting of a LIMS and an Electronic Laboratory Notebook (ELN) that automates interfaces, integrating information flow from every machine in a laboratory, from initial sample shipment to final reporting of results. By reducing administrative time, SLims frees staff members to devote themselves to unlocking insights that improve outcomes.”
The GeneReader NGS System, launched in late 2015, is the first truly complete Sample to Insight workflow that provides a simpler, more cost-effective way for clinical testing laboratories to take advantage of NGS technology and improve outcomes. In June 2016 QIAGEN expanded the GeneReader for use with non-invasive liquid biopsies, adding to its use with FFPE tissue samples. QIAGEN today also announced the relaunch of the System in the U.S. market based on several upgrades made to its new sequencing chemistry, which showed excellent performance data generated with QIAGEN’s GeneRead QIAact Actionable Tumor Panel.
GeneRead Link middleware, the only standardized interface to manage NGS data from sample preparation to reporting of results, interfaces with any LIMS to maximize efficiency and provide compliant management.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
A spin-off of the University of Ghent (Belgium), Genohm was originally established in Ghent as a 2 person bioinformatics shop in 2002. Building upon extensive bioinformatics consulting expertise within the life sciences, biotechnology and university hospital research markets, in 2010 Genohm put together SLims, a unique LIMS+ELN or Laboratory Information Management System. In May 2011 Genohm opened its new Headquarters at the EPFL Innovation Park in Lausanne, Switzerland and in 2016 a US branch in Durham, NC, while keeping its European branch offices in Ghent. Today Genohm, a ISO 9001 certified company, serves customers in Europe, the Middle East and the US. Further information can be found at https://www.genohm.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women’s health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Dr. Thomas Theuringer
Head of Marketing and Communication